Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with Generalized Anxiety Disorder

INTRODUCTION: The pilot clinical study of GB-115, a new peptide antagonist of central cholecystokinin-1 receptors, revealed that drug was clinically effective in patients with generalized anxiety disorder (GAD) at dose 6 mg daily. Here, we provide results of post-hoc analysis of changes of anxiety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorofeeva, O., Syunyakov, T., Metlina, M., Ivashkina, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564032/
http://dx.doi.org/10.1192/j.eurpsy.2022.981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564032/
http://dx.doi.org/10.1192/j.eurpsy.2022.981

Ejemplares similares